ERBB2 and breast carcinoma: A cohort12 of 434 Chinese patients with HER2‐low breast cancer with multiomics data has shown that HER2‐low is more distinct from HER2‐zero in triple negative breast cancer (TNBC) compared with hormone receptor‐positive breast cancer.